This document discusses tumours of the ear, including both benign and malignant types. It provides details on the epidemiology, risk factors, pathology, diagnosis and treatment of various tumours such as basal cell carcinoma, squamous cell carcinoma, melanoma, and others. Treatment options discussed include surgical excision with various techniques depending on tumour size and location, Mohs surgery, radiation therapy, and reconstruction after tumour removal. Staging criteria and classifications of temporal bone tumours are also presented.
Includes brief info about epidemiology, etiology, TNM staging, types,symptoms and management of CA larynx/ larynx carcinoma.
glottic ,subglottic and supraglottic carcinoma of larynx is also discussed with the individual management.
Includes brief info about epidemiology, etiology, TNM staging, types,symptoms and management of CA larynx/ larynx carcinoma.
glottic ,subglottic and supraglottic carcinoma of larynx is also discussed with the individual management.
8% of all bone tumors present in spine
25-30% of bone tumors are benign
Peak age: 2-3rd decade
Posterior element involved: osteoid osteoma, osteoblastoma, aneurysmal bone cyst
Anterior element involved: giant cell tumor, hemangioma, eosinophilic granuloma
Similar to Tumours of external and middle ear (20)
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdfAnujkumaranit
Artificial intelligence (AI) refers to the simulation of human intelligence processes by machines, especially computer systems. It encompasses tasks such as learning, reasoning, problem-solving, perception, and language understanding. AI technologies are revolutionizing various fields, from healthcare to finance, by enabling machines to perform tasks that typically require human intelligence.
Couples presenting to the infertility clinic- Do they really have infertility...Sujoy Dasgupta
Dr Sujoy Dasgupta presented the study on "Couples presenting to the infertility clinic- Do they really have infertility? – The unexplored stories of non-consummation" in the 13th Congress of the Asia Pacific Initiative on Reproduction (ASPIRE 2024) at Manila on 24 May, 2024.
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...kevinkariuki227
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...GL Anaacs
Contact us if you are interested:
Email / Skype : kefaya1771@gmail.com
Threema: PXHY5PDH
New BATCH Ku !!! MUCH IN DEMAND FAST SALE EVERY BATCH HAPPY GOOD EFFECT BIG BATCH !
Contact me on Threema or skype to start big business!!
Hot-sale products:
NEW HOT EUTYLONE WHITE CRYSTAL!!
5cl-adba precursor (semi finished )
5cl-adba raw materials
ADBB precursor (semi finished )
ADBB raw materials
APVP powder
5fadb/4f-adb
Jwh018 / Jwh210
Eutylone crystal
Protonitazene (hydrochloride) CAS: 119276-01-6
Flubrotizolam CAS: 57801-95-3
Metonitazene CAS: 14680-51-4
Payment terms: Western Union,MoneyGram,Bitcoin or USDT.
Deliver Time: Usually 7-15days
Shipping method: FedEx, TNT, DHL,UPS etc.Our deliveries are 100% safe, fast, reliable and discreet.
Samples will be sent for your evaluation!If you are interested in, please contact me, let's talk details.
We specializes in exporting high quality Research chemical, medical intermediate, Pharmaceutical chemicals and so on. Products are exported to USA, Canada, France, Korea, Japan,Russia, Southeast Asia and other countries.
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
Ethanol (CH3CH2OH), or beverage alcohol, is a two-carbon alcohol
that is rapidly distributed in the body and brain. Ethanol alters many
neurochemical systems and has rewarding and addictive properties. It
is the oldest recreational drug and likely contributes to more morbidity,
mortality, and public health costs than all illicit drugs combined. The
5th edition of the Diagnostic and Statistical Manual of Mental Disorders
(DSM-5) integrates alcohol abuse and alcohol dependence into a single
disorder called alcohol use disorder (AUD), with mild, moderate,
and severe subclassifications (American Psychiatric Association, 2013).
In the DSM-5, all types of substance abuse and dependence have been
combined into a single substance use disorder (SUD) on a continuum
from mild to severe. A diagnosis of AUD requires that at least two of
the 11 DSM-5 behaviors be present within a 12-month period (mild
AUD: 2–3 criteria; moderate AUD: 4–5 criteria; severe AUD: 6–11 criteria).
The four main behavioral effects of AUD are impaired control over
drinking, negative social consequences, risky use, and altered physiological
effects (tolerance, withdrawal). This chapter presents an overview
of the prevalence and harmful consequences of AUD in the U.S.,
the systemic nature of the disease, neurocircuitry and stages of AUD,
comorbidities, fetal alcohol spectrum disorders, genetic risk factors, and
pharmacotherapies for AUD.
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Oleg Kshivets
RESULTS: Overall life span (LS) was 2252.1±1742.5 days and cumulative 5-year survival (5YS) reached 73.2%, 10 years – 64.8%, 20 years – 42.5%. 513 LCP lived more than 5 years (LS=3124.6±1525.6 days), 148 LCP – more than 10 years (LS=5054.4±1504.1 days).199 LCP died because of LC (LS=562.7±374.5 days). 5YS of LCP after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (78.1% vs.63.7%, P=0.00001 by log-rank test). AT significantly improved 5YS (66.3% vs. 34.8%) (P=0.00000 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0—N12 (rank=2), thrombocytes/CC (3), erythrocytes/CC (4), eosinophils/CC (5), healthy cells/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), stick neutrophils/CC (9), monocytes/CC (10); leucocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0).
CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) LC cell dynamics; 10) surgery type: lobectomy/pneumonectomy; 11) anthropometric data. Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.
Prix Galien International 2024 Forum ProgramLevi Shapiro
June 20, 2024, Prix Galien International and Jerusalem Ethics Forum in ROME. Detailed agenda including panels:
- ADVANCES IN CARDIOLOGY: A NEW PARADIGM IS COMING
- WOMEN’S HEALTH: FERTILITY PRESERVATION
- WHAT’S NEW IN THE TREATMENT OF INFECTIOUS,
ONCOLOGICAL AND INFLAMMATORY SKIN DISEASES?
- ARTIFICIAL INTELLIGENCE AND ETHICS
- GENE THERAPY
- BEYOND BORDERS: GLOBAL INITIATIVES FOR DEMOCRATIZING LIFE SCIENCE TECHNOLOGIES AND PROMOTING ACCESS TO HEALTHCARE
- ETHICAL CHALLENGES IN LIFE SCIENCES
- Prix Galien International Awards Ceremony
5. Basal cell & Squamous cell carcinoma
Epidemiology:
• Mean age 70 yr
• Lower in darker-skinned ethnic group
• Basal cell (BCC)>Squamous (SCC)>Melanoma (MM)
• 85-95% of all BCC & SCC occur in head & neck region
• 12% of these tumours in auricle
• SCC: External ear & upper face
• BCC: Midface & auricle
6. Pathophysiology/Risk factors
1. Sun exposure: ultraviolet radiation (SCC> BCC)
2. Actinic keratosis: small, scaly lesions, common
(Actinic keratosis60% SCC)
3. Keratoacanthoma: benign conditionspontaneous resolution or
SCC
4. Exposure to radiation
5. Immunosupression: 5-16 fold
7. 7. Xeroderma pigmentosa: Autosomal recessive, DNA repair
mechanism, SCC and BCC at young age
8. Trauma
9. Frostbite
10. Psoriasis
11.Aflatoxin B
12. Nevoid basal cell syndrome (Gorlin’s syndrome): Autosomal
dominant, multiple pigmented BCC once reach puberty
13. Chronic otitis externa
8. Pathology
Basal Cell Carcinoma (BCC)
Variants of BCC:
Nodular: most common, least aggressive,
bleeds easily
Ulcerative: “Rodent ulcer”
Pigmented:
Superficial:
Morpheaform/sclerosing: Most aggressive,
highest rate of recurrence
Basaloid squamous
9. Squamous cell carcinoma (SCC)
• Plaque to nodule or ulcer
• Variants of SCC, less common than BCC
• Keratin pearl
• Variants of SCC:
Nodular
Ulcerative
Pigmented: confused with melanoma
Spindle shaped subtype: radiated skin
Verrucous- locally destructive
Basaloid squamous
Adenoid squamous
10. Diagnosis
• Clinical evaluation
• Biopsy:
• Lesion with change in colour, size, shape,
friable or ulcerated
Punch biopsy- preserves architecture of the
lesion for histologic analysis, depth of
lesion, excision with precise margin.
• Imaging studies (CT, MRI): rarely needed
13. Limitations of AJCC staging in malignancy of ear
Thin skin of ear early involvement of deeper structure T4
T4- doesn’t have similar prognosis or require radical treatment
like in other sites
Staging based on sizeless practical (unique anatomy of ear)
Even small tumours eg. preauricular, concha or
tragusextensive surgery
Doesn’t account for different histologies: BCC may act
differently than SCC
15. Surgical Excision
• Most common form of treatment
• Appropriate margin of resection difficult
• BCC:
– 8 mm for <3 cm
– 1.5 cm for >3cm (Bumstead et al., 1981)
• 2-3 mm for <1cm
• 3-5mm for 1-2 cm
• 7-10mm-morpheaform histology (Scotto et al., 1983)
• SCC:
1-2 cm surgical margin (Bumstead et al., 1981)
16. Mohs’ Surgery
Dr. Frederick Mohs in 1941
• Serial horizontal sectioning of tumor & surrounding tissue with
immediate microscopic analysisconfirm the margins clear of
tumour
• Fixed in vivo with zinc chloride
• Several advantages over traditional wide local excision
Horizontal section of entire margin analysis of small islands of
tumor cells
Avoids unnecessary excision of normal tissue
Less recurrences following Mohs’ surgery
17. • Recommended method for
Malignancy arising in vital area
Recurrent or previously treated area
Aggressive histopathology
Larger carcinoma >1cm
Poorly defined margin
18. • Mohs’ surgery: overall cure rates for auricular carcinoma- 98% for
BCC and 92% for SCC (Mohs F, 1998 and Niparko et al., 1990)
19. Other surgical techniques:
For small non-agressive tumours with clearly
defined margin
• Curettage and electrodesiccation
• Cryosurgery: -40°c, cure rate exceeds 95%
Cryogun used to
spray liquid nitrogen
21. 5 year recurrence rates for previously treated BCC
(Rowe et al., 1989)
22. Radiation Therapy
• Advantages
Avoids tissue defects, unfit patients, refuse surgery & tumour
involving adjacent areas
• Disadvantages
Multiple treatments, more costly, risk of radiation induced tumour
• Regimen vary from center to center
• Common regimen
– 20 Gy, 2# very small tumor
– 30-40 Gy for 2-4 cm volume
– 60-65 Gy for large tumors
• Cure rate comparable to surgery for <1 cm
23. • Non surgical options
– Topical 5-Fluoruracil (5-20% concentration)
– Intralesional interferon-alpha
– Use of photodynamic therapy
• Treatment of recurrent disease- more difficult
Aggressive tumours, margins less precise and disrupted
anatomy due to prior treatmentreconstruction more difficult
• Treatment of metastatic neck disease
– Overall recurrence rate for BCC- <5% and SCC- 10 to 15%
– Elective neck dissection - Controversy
28. Malignant melanoma
Epidemiology:
• Incidence increasing
• Accounts for majority of deaths from skin malignancies
• 7-13% of all head & neck malignancy, 1% of all melanoma
• 65-79 yr
• Lower in black & dark skinned people
• Lower in woman- more attention paid on appearance & more
regular physician visits
31. Diagnosis
• Keen eyes, diligent physical examination
• Majority arises from pre-existing naevi
• A B C D (Asymmetry, Border, Color, Diameter)
• Excisional biopsy
• HPE: Variable
• Immunohistochemistry: S-100, Vimentin, HMB-
45
• Role of imaging
32.
33.
34. Treatment
Surgery
• Tumour thickness- correlates with survival
• 1cm for 1mm thickness & 2cm for larger
• Mohs’ Surgery: Controversy
• Overall cure rate: 68%
• Recurrence between 1-3 yr, follow up every 1-2 month
• Role of radiation
• Traditionally considered to be radioresistant
• For local control of paritally resected melanoma
35. Treatment of neck metastasis
• 17% nodal disease at presentation
• Auricular melanoma risk 42%
• Parotid & upper jugular digastric
• Radical or modified neck dissection for melanoma- No studies
to demonstrate differences
• Post-operative RT
• Elective neck dissection: Controversy
• Treatment of advanced disease: 10% 10 yr survival
36. Other tumours
• Merkel cell carcinoma:
One of the most aggressive
High recurrence and metastases rate
Neuroendocrine tumour
Pleuripotent basal cells
Rapidly growing, firm, nodular
Wide local excision
Radiosensitive
37. • Malignant fibrous histiocytoma
• Dermatofibrosarcoma
• Angiosarcoma
• Metastatic disease from other sites
39. Contd…
• All three primordial layers temporal bone spectrum of
neoplasms
• Benign & malignant
• Neither AJCC nor the UICCsystem for classifying temporal
bone tumours
• Difference in growth rate & sites of origin varied
presentations
41. Benign tumours of EAC and middle ear cleft
Exostosis
• Benign
• Deep part of bony canal, adjacent to TM
• Smooth, sessile, multiple, inner part of
meatus & bilateral
• Relationship with cold water exposure
• Asymptomatic
• >80% stenosis: Symptomatic
48. Pathophysiology/Risk factors:
• Risk factors - not well defined
• Chronic otitis media:
Strongly suggests but not invariably associated
• Human papilloma virus: HPV 16 and 18 (Jin et al., 1997)
• Radium dial workers
• External beam radiation
• Ultraviolent radiation and other forms of radiation: no
strong link?
49. • Incidence: old age
EAC
• Squamous cell carcinoma: most
common
• Hidradenocarcinoma
• BCC, melanoma & mucoepidermoid
carcinoma
Middle ear
• SCC (80%), adenocarcinoma, BCC &
adenoid cystic carcinoma
Well differentiated SCC of EAC
50. Behavior of SCC of external auditory canal & middle ear
• Escape from the EAC and middle ear
cleft several directions
• Superiorly
• Posteriorly
• Anteriorly
• Inferiorly
• Medially
• Laterally
51.
52.
53. MRI coronal view of the temporal bone showing mass from
the left mastoid area extending out to involve external ear
canal and skin
54. MRI axial view of the temporal bone showing tumour
eroding left lateral semicircular canal
55. MRI axial view showing the left temporal lobe involvement
and cerebellar compression
56. Signs & Symptoms
• Change in pattern: may be only clue
• Growth
• Pain
• Discharge
• Deteriorating hearing
• Facial paralysis, hemi facial spasm
• Lower cranial nerve palsy
• Trismus
• Lymphadenopathy
Differential diagnosis: Otitis Externa,
COM
An exophytic mass within EAC
61. Treatment
• Surgical treatment followed by radiotherapy
• Extent of surgery controversial
• En block Vs Piecemeal
• Radical mastoidectomy
• Problem of local recurrence
• Extensive surgery Complete temporal bone resection
62. Sleeve Resection
• Tumours confined to skin & soft
tissue of cartilaginous portion of
EAC
• T 1
• Red line
• Incision – medial and lateral
• Involved skin & underlying cartilage
resectedwide meatoplasty
• Split-thickness skin graft
63. Lateral Temporal Bone Resection
• Tumours involving bony & cartilaginous
part (not involved annulus & tympanic
cavity)
• T 2
• Entire external auditory canal + TM +
Malleus + Incus resected ‘en-bloc’
(Blue Line)
• Facial nerve dissected from stylomastoid
foramen to pes anserinus
• Superficial parotidectomy
• Eustachian tube - plugged
67. Modified Lateral Temporal Bone Resection
• Tumor extension to tympanic cavity or mastoid air cell
• T3
• Facial nerve sacrificed
• Posterior petrosectomy- bone removal posteriorly back to the
transverse sinus & posterior fossa dura
• Tegmen tympani removed
• Perilabyrinthine, retrofacial cells opened down to jugular bulb
• More extensive defect: temporalis and sternocleidomastoid
muscle flaps rotated inobliterate the defect
68. Subtotal Temporal Bone Resection
• Extensively encroach tympanic
cavity
• T3
• Entire temporal bone lateral to
petrous carotid artery en bloc
• If necessary: Portion of dura,
sigmoid sinus, parotid gland,
ramus of mandible, subtotal
parotidectomy
• Facial nerve transected
69. Total Temporal Bone Resection
• Sacrifice of carotid artery
• T 4
Light green line
• Most important decision is not to
operate at all (Gustafson et al., 2003)
• Invasion of cavernous sinus, ICA,
infratemporal fossa, paraspinous
muscle-surgically incurable
70. Radiation therapy
• Radiotherapy for curative treatment – limited success
• 5-year cure rate RT alone 28.7%, RT+ Surgery 59.6%
(Zhang et al.,1999)
• Higher doses- toxicity to brainstem
• Adjuvant therapy & palliation
• Side effects and complications- osteoradionecrosis, facial nerve
pasly & brain necrosis
• No randomized study-effect of radiation on survival & recurrence
71. Treatment of metastasis
• Regional & distant metastasis from temporal bone malignancy-low
• Nodal diseases at the time of presentation- 9% to 18%
(Pensak ML, 2003)
• Upper jugulodiagastric & parotid nodes- most commonly involved
• Neck dissection - no improvement in survival
• Superficial parotidectomy in every patient with more than
superficial disease & neck dissection reserved for known
adenopathy
72. Other epithelial malignancy:
• BCC
• Melanoma
Glandular malignant lesion
• Adenoid cystic carcinoma- most common
glandular malignancy in EAC
• Ceruminous adenocarcinoma
• Mucoepidermoid carcinoma
Sarcomas:
Fibrosarcoma, osteogenic sarcoma,
Ewing’s sarcoma, Kaposi’s sarcoma
& chondrosarcoma
Meatastasis to temporal bone: breast, lung,
kidney, stomach, brochus & prostate
Secondary tumor of temporal bone
Spreading from adjaent areas: Parotid,
nasopharyngeal, auricular & meningioma
73.
74. Tumours in childhood
Rhabdomyosarcoma (RMS)
• Rhabdo-rod shaped, myo- muscle
• Most common soft tissue sarcoma in children
• Ear 3rd
most common after nasopharynx & orbit
• Meningeal, parameningeal & orbital
• Majority - before 12 years (average age - 4.4 years)
• Types:
1. Embryonal–nearly all of the head & neck rhabdomyosarcoma
2. Alveolar – worst prognosis
3. Pleomorphic
4. Botryoid – best survival
75. RMS contd…
Clinical features: (Prat J, 1997)
1. Mass in ear region 56%
2. Aural polyp 54%
3. Ear discharge 40%
4. Bleeding from ear 30%
5. Ear pain 22%
6. Hearing loss 14%
7. Facial paralysis 14%
Diagnosis
• Biopsy
• PCR
• Bone marrow
• CT
• MRI
76. International Rhabdomyosarcoma Study (IRS)
Based on tumour resectability:
• Group I - Tumour completely removed
• Group II - Microscopic residual tumour, involved regional nodes,
or both
• Group III - Gross residual tumour
• Group IV - Distant metastatic disease